Clinical Policy: Vigabatrin (Sabril)
Reference Number: CP.PHAR.169
Effective Date: 02.01.16
Last Review Date: 11.19
Line of Business: HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Vigabatrin (Sabril®) is an anticonvulsant.

FDA Approved Indication(s)
Sabril is indicated:
- For the treatment of refractory complex partial seizures as adjunctive therapy in patients ≥ 10 years of age who have responded inadequately to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss; Sabril is not indicated as a first line agent for complex partial seizures
- For the treatment of infantile spasms as monotherapy in infants 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Sabril is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Infantile Spasms (must meet all):
      1. Diagnosis of infantile spasms;
      2. Prescribed by or in consultation with a neurologist;
      3. Age between 1 month to 2 years;
      4. Dose does not exceed 150 mg/kg/day.
      
      Approval duration: 3 months

   B. Refractory Complex Partial Seizures (must meet all):
      1. Diagnosis of refractory complex partial seizures;
      2. Prescribed by or in consultation with a neurologist;
      3. Age ≥ 10 years;
      4. Sabril will be used as adjunctive therapy;
      5. Failure of three preferred alternative anticonvulsant drugs (see Appendix B for examples);
      6. Dose does not exceed (a or b):
         a. Pediatric members age 10 to 16 years: 2,000 mg/day (members > 60 kg should be dosed as adults);
b. Adults age ≥ 17 years: 3,000 mg/day.

Approval duration: 6 months

C. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid.

II. Continued Therapy
A. Infantile Spasms (must meet all):
1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Sabril for infantile spasms and has received this medication for at least 30 days;
2. Age between 1 month to 2 years;
3. Member is responding positively to therapy;
4. If request is for a dose increase, new dose does not exceed 150 mg/kg/day.

Approval duration: 12 months or up to 2 years of age, whichever is less

B. Refractory Complex Partial Seizures (must meet all):
1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Sabril for refractory complex partial seizures and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed one of the following (a or b):
   a. Pediatric members age 10 to 16 years: 2,000 mg/day (members > 60 kg should be dosed as adults);
   b. Adults (age ≥ 17 years): 3,000 mg/day.

Approval duration: 12 months

C. Other diagnoses/indications (must meet 1 or 2):
1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid or evidence of coverage documents.
### IV. Appendices/General Information

**Appendix A: Abbreviation/Acronym Key**  
FDA: Food and Drug Administration

**Appendix B: Therapeutic Alternatives**  
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Examples</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticonvulsants for partial seizures</td>
<td>carbamazepine (Tegretol®), felbamate (Felbatol®), gabapentin (Neurontin®), lamotrigine (Lamictal®), levetiracetam (Keppra®), oxcarbazepine (Trileptal®), phenytoin (Dilantin®), tiagabine (Gabitril®), topiramate (Topamax®), valproic acid (Depakene®), divalproex sodium (Depakote®), zonisamide (Zonegran®)</td>
<td>Varies according to the agent used</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

**Appendix C: Contraindications / Boxed warnings**
- Contraindication(s): none reported
- Boxed warnings: Permanent vision loss
  - Sabril can cause permanent bilateral concentric visual field constriction, including tunnel vision that can result in disability. In some cases, Sabril may also decrease visual acuity.
  - Risk increases with increasing dose and cumulative exposure, but there is no dose or exposure to Sabril known to be free of risk of vision loss.
  - Risk of new and worsening vision loss continues as long as Sabril is used, and possibly after discontinuing Sabril.
  - Baseline and periodic vision assessment is recommended for patients on Sabril. However, this assessment cannot always prevent vision damage.
  - Because of the risk of permanent vision loss, Sabril is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Vigabatrin REMS Program. Further information is available at www.vigabatrinrems.com.

### V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infantile spasms</td>
<td>50 mg/kg/day (25 mg/kg PO BID); increase total daily dose in increments of 25 mg/kg/day PO every 3 days to 50 mg/kg/day</td>
<td>150 mg/kg/day (75 mg/kg twice daily)</td>
</tr>
<tr>
<td>Complex partial seizures</td>
<td>Adults (&gt; 17 years): 1,000 mg/day (500 mg PO BID); increase total daily</td>
<td>Adults: 3000 mg/day (1,500 mg twice daily)</td>
</tr>
</tbody>
</table>
**Indication** | **Dosing Regimen** | **Maximum Dose**
--- | --- | ---
 | dose weekly in 500 mg/day increments to 3,000 mg/day | Pediatrics: 2,000 mg/day (1,000 mg twice daily)
 | Pediatrics (10-16 years): 500 mg/day (250 mg PO BID); increase total daily dose weekly in 500 mg/day increments to 2,000 mg/day; Patients weighing more than 60 kg should be dosed according to adult recommendations.

**VI. Product Availability**
- Tablet: 500 mg
- Powder for oral solution: 500 mg

**VII. References**

**Reviews, Revisions, and Approvals**

<table>
<thead>
<tr>
<th>Policy split from CP.PHAR.56.HP Acthar and Sabril. Criteria: added maximum dose. Substituted participation in SHARE program for vision assessment criteria. Background: limited to Description/MOA, FDA approved indications and safety information. Appendices: removed Appendix F and incorporated pertinent information about the SHARE program into the criteria.</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infantile spasms: Lower age limit of one month is removed and left to provider discretion; dosing is removed given verification</td>
<td>02.17</td>
<td>02.17</td>
</tr>
</tbody>
</table>
challenges around weight-based dosing; monotherapy is removed since other seizure medications are available without a PA making verification problematic.
Complex partial seizures: Adjunctive therapy is defined and examples of anticonvulsant therapies are added per the PI; dosing is added to the continued approval section.
Informational footnotes regarding dosing are added to both initial approval sections.
Efficacy criteria are added to both continued approval sections.
Classification of seizures per ILAE is added at Appendix B.
PI black box warning is restated verbatim at Appendix C.
Periodic visual monitoring is required under the REMS program and so is not stated separately in the criteria; documentation of REMS enrollment also is removed from criteria sets since it is required separately under the REMS program for both members and providers.
Classification and guideline/consensus documentation is added to reference section.

- added criteria of Abnormal electroencephalogram (EEG) confirming diagnosis of infantile spasms;
- extended approval durations from 3/6 months to 6/12 months
- removed age criteria in continued approval for infantile spasms, as it is already criteria for initial approval.

3Q 2018 annual review: added HIM line of business to existing Medicaid line of business policy; Medicaid: for infantile spasms: removed abnormal EEG requirement to confirm diagnosis and added specialist requirement, extended initial approval duration from 4 weeks to 3 months, added back age requirement on re-auth; added “or up to 2 years of age, whichever is less” to continued approval duration; modified continued therapy to allow for continuity of care for infantile spasms and complex partial seizures; for complex partial seizures: added specialist requirement; references reviewed and updated.

3Q 2019 annual review: For Complex partial onset seizures: changed criteria verbiage from “inadequate response” to “failure of”, clarified to require failure of two alternatives; moved BBW and REMS info from Appendix D to Appendix C; references reviewed and updated.

For Refractory Complex Partial Seizures (CPS): Modified failure of two preferred alternative anticonvulsant drugs to a failure of three agents; references reviewed and updated.

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.
Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

For Health Insurance Marketplace members, when applicable, this policy applies only when the prescribed agent is on your health plan approved formulary. Request for non-formulary drugs must be reviewed using the formulary exception policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.